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After decades of stagnation, research in tuberculosis (TB) therapeutics is experiencing a renais-
sance, with an increasing number of new and repurposed compounds undergoing evaluation
as part of novel treatment regimens. This is much welcome progress, since current regimens
are not ideal due to the long duration of treatment required, toxicities, drug–drug interactions,
and high costs—particularly for treatment of the various forms of drug-resistant TB (DR-TB).
The development of new TB drugs is, however, complex, lengthy, and costly [1], and the
pathway to proven new TB treatment regimens is fraught with numerous obstacles and uncer-
tainties [2]. In this PLOS Medicine Collection, “Advances in Clinical Trial Design for Develop-
ment of New Tuberculosis Treatments,” we highlight key obstacles and identify potential
solutions that will help avoid misadventures and in turn maximize the likelihood of success in
identifying new drugs and regimens through a rejuvenated global interest in TB therapeutics.
With the emergence of several new chemical entities expected to transition into clinical testing
in the next 5 years, the possibility of ultrashort (i.e., requiring treatment for weeks rather than
months) regimens for active TB is no longer fanciful. Investigators in the field have learned
much from recent TB clinical studies, and we anticipate that well-designed and conducted
clinical trials evaluating the next generation of drugs and regimens will, with some good for-
tune, lead to identification of the ultrashort, safe, and effective regimens so desperately needed.
Treatment of TB relies on a synergistic combination of drugs (traditionally categorized as
bactericidal or sterilizing) administered for sufficient time to achieve definitive nonrelapsing
cure and to prevent selection of drug-resistant mutants [3]. The treatment of drug-susceptible
TB (DS-TB) is well codified, with a standard combination of 4 drugs given for a duration of 6
months [4]. This regimen is the result of a series of clinical studies conducted in several coun-
tries, which demonstrated the efficacy of short-course regimens of 6–8 months’ duration in
patients with pulmonary disease [5]. These trials played a key role in the establishment of
short-course chemotherapy worldwide, allowing treatment of DS-TB to be based on the best
available evidence [6]. Since then, clinical trials and programmatic experience have shown that
the standard 6-month isoniazid/rifampicin-based regimen, when adhered to, performs consis-
tently well in a wide variety of settings and can serve as a reliable control regimen against
which investigational regimens can be compared [4]. The situation is, however, more compli-
cated for DR-TB. In the absence of controlled trials comparing different regimens to a recog-
nized “gold standard” treatment, the current recommendations for therapy rely on early-phase
culture-conversion results, observational studies, and a few late-phase clinical trials [7]. The
number and type of drugs required to treat patients with DR-TB has long been a matter of
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debate and controversy despite agreement on basic principles such as the minimum number
of drugs to use and minimum duration of treatment. As a result, the efficacy of recommended
DR-TB treatment regimens has been shown to vary widely in clinical studies and programs
[8,9].
The need for solid evidence from randomized controlled trials has led the TB research com-
munity to adopt a design widely used in HIV research for the development of new antiretrovi-
rals, in which patients are randomized to receive either a new drug or placebo in addition to a
defined “optimized background regimen,” usually the best available standard of care [10]. This
approach has been used in the development of bedaquiline [11] and delamanid [12], the first
two new drugs approved for TB treatment since the late 1980s. While this research design
assesses the added value, if any, of a given investigational drug, the approach leaves unresolved
the question of the optimal drug combination in which to include the new agent [13]. As a
result, additional clinical trials are then needed to identify the best options for treatment using
new drugs in variable combinations, resulting in additional years of delay in producing the
best evidence for global policy-making decisions. In parallel, practical recommendations are
needed for the use of any newly approved drugs, along with guidance for countries and pro-
grams as to which combinations are safe, tolerable, and efficacious, an endeavor that requires
systematic reviews and meta-analyses of observational cohort studies and programmatic data,
which carry significant limitations. This approach is not sustainable, practical, or efficient and
raises the need for a shift to a more efficient and seamless development process that allows the
testing of novel treatment regimens, including one or more promising new or repurposed
medicines, early in the clinical development pathway. Some stakeholders, such as the TB Alli-
ance, therefore proposed a “unified approach to TB regimen development” addressing the
joint development of new drugs and regimens for both DS-TB and DR-TB [14]. Also, the
International Union against Tuberculosis and Lung Diseases opted to investigate the safety
and efficacy of a set combination regimen of 9–12-months’ duration for the treatment of
DR-TB in parallel through a randomized controlled trial [15] and observational studies under-
taken within programmatic research conditions [16]. However, the availability of results from
these various studies at different points in time and questions arising from the challenge of
interpreting and integrating data from various methodologies were found to limit the ade-
quacy of these complementary approaches for development of therapies [17].
Duly concerned with the need to base its normative treatment recommendation on the best
available evidence [18], and to produce guidelines that would be readily usable in daily practice
in all settings, WHO opted to establish minimal and optimal benchmarks for TB regimen
development using industry-accepted target product profile (TPP) principles [19]. These TPPs
for new anti-TB regimens, referred to as “target regimen profiles” (TRPs), describe the mini-
mum and optimal attributes and characteristics of future TB regimens to guide the develop-
ment process [20]. A population-level modeling analysis evaluating the potential impact of
various regimen characteristics on the TB epidemic highlighted the paramount importance of
regimen efficacy to exert the largest impact on reduction of TB cases and deaths, both for
DS-TB and DR-TB [21]. Other characteristics such as shorter duration of, or increased adher-
ence to, treatment were shown to have important effects by enabling more people with TB to
receive appropriate and timely therapy. Most importantly, this model highlighted the difficulty
of improving all potential characteristics simultaneously in a single regimen, leading develop-
ers to consider weighing in inevitable trade-offs (e.g., higher cure rates may be difficult to
achieve simultaneously with shorter treatment duration, and simpler or better-tolerated regi-
mens may be less robust to emergence of drug resistance) that are duly addressed in the TRPs.
Given the recommended regimen characteristics, the implementation of TRPs stimulated
the question of which clinical trial designs and features should be optimally used for the
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development of new anti-TB regimens. Major challenges exist along the current lengthy devel-
opment pathway [1], including the lack of direct indicators of treatment response, the lack of
reliable surrogate markers of treatment outcomes, and the lack of predictive quantitative rela-
tionships between Phase II and Phase III outcomes [22]. To accelerate and streamline the
development of new TB regimens, the therapeutics research community needs to establish
clear and rationally justified approaches for the choice of drug combinations, trial design,
selection of endpoints, and analysis [23,24], taking into account new developments in individ-
ual drugs’ pharmacokinetic and pharmacodynamic characteristics, microbiological aspects,
use of biomarkers, standardization of approaches and data collection, as well as drug effects in
key patient populations.
From the regimen developer’s perspective, it is apparent that a new treatment regimen
must bring a value proposition, beyond efficacy or safety targets. Products with broader appli-
cations (e.g., for eligible populations) gain in terms of delivery and scalability/distribution or
cost and can bring substantial impact and value that define the developmental pathway. Spon-
sors and donors should evaluate the needs of the market and develop programs based on those
needs. In conjunction, decisions about progress from Phase II to Phase III studies continue to
involve significant uncertainty, and these limitations need to be considered when designing
Phase III trials. Also, the issue of the control groups most appropriate for a given trial situation
needs careful consideration. It thus appears that each development program needs to deter-
mine the most appropriate approach to trial design, depending on the situation and the ques-
tions to be addressed.
From both programmatic and patient perspectives, the recent pooled individual patient-
level analysis of three treatment-shortening trials examining the efficacy and safety of 4-month
combination regimens, including third-generation fluoroquinolones for the treatment of
DS-TB [25–27], provided critically important insights relevant to TB treatment in the field and
to therapeutics research [28]. Whereas these trials independently failed to show noninferiority
of the 4-month experimental regimens tested, as compared to the 6-month control regimen,
80% of patients were cured. The pooled analysis of these trials found that patients with mini-
mal disease, defined as low bacterial burden or absence of lung cavities, would be eligible for
4-month treatments [28]. Conversely, patients with high baseline smear, cavitation on chest X-
ray, HIV coinfection, and low body mass index defined hard-to-treat phenotypes that would
need more than the standard 6-month treatment duration to achieve the highest possible cure
rates. In addition, even minimal nonadherence (i.e., missing 1 in 10 doses) to the current stan-
dard regimen was found to be a significant risk factor for unfavorable outcome, independent
of treatment duration. These findings provide a strong evidence-based framework for investi-
gating different approaches to achieving better patient-oriented treatment—such as the strati-
fied medicine approach—and emphasize the importance of maximizing adherence in clinical
trials and in real-world conditions.
These issues illustrate the need for obtaining maximally informative and reliable data from
controlled trials, as these are paramount for the development of policy for wide public health
use and for guideline development. To address these coherently, in March 14–16, 2018, WHO
organized a technical consultation on “Advances in Clinical Trial Design for New TB Treat-
ments” to identify and outline, through expert consensus, the optimal characteristics of clinical
trial designs to inform policy guidance for the development of new TB regimens. Building on
the lessons learned from the rich history of TB clinical trials, the WHO technical consultation
[29] reviewed the various research designs and tools currently used in the conduct of clinical
trials for development of new TB treatments and made a series of proposals to advance these
further, seeking to move from evolutionary change informed by history to a bolder approach
to innovation geared to the future. These are the aims of this PLOS Medicine Collection, which
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we are launching on World TB Day 2019, beginning with the accompanying paper from Pat-
rick Phillips and colleagues [30] on the changing landscape of clinical trial design for develop-
ment of TB therapeutics. Further articles will be added to the Collection in due course, and the
Collection will be available in its entirety alongside this paper once all the articles have been
published.
References
1. Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med.
2007; 13:290–4. https://doi.org/10.1038/nm0307-290 PMID: 17342142
2. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, et al. New drugs for the
treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012;
205 Suppl 2:S241–9.
3. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med. 1980; 1
(2):231–41. PMID: 6794976
4. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care,
2017 update. WHO/HTM/TB/2017.05. Geneva: World Health Organization; 2017.
5. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British
Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications. Int J
Tuberc Lung Dis 1999; 3 (Suppl):S231–S279.
6. Cochrane AL. 1931–1971: a critical review, with particular reference to the medical profession. In: Teel-
ing-Smith G, Wells N, eds. Medicines for the year 2000. London, UK: Office of Health Economics,
1979, pp 1–11.
7. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc
Lung Dis 2006; 10:829–37. PMID: 16898365
8. Mirzayev F, Zignol M, Danilovitz M, Hurtado N, Leimane V, Malla P, et al. Treatment outcomes from 9
projects approved by the Green Light Committee between 2000 and 2003. Abstract to the 38th World
Conference on Lung Health. 8–12 November 2007. Cape Town, South Africa.
9. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al. Adverse events in
the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative. Int J Tuberc
Lung Dis 2004; 8:1382–4. PMID: 15581210
10. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of
multi-drug resistant tuberculosis. PLoS Med. 2007; 4(11):e292. https://doi.org/10.1371/journal.pmed.
0040292
11. Diacon AH, Pym A, Grobusch M, De Los Rios JM, Gotuzzo E, Vasilyeva I, et al. The diarylquinoline
TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397–405. https://doi.org/10.
1056/NEJMoa0808427 PMID: 19494215
12. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al.
Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012; 366(23):2151–60.
https://doi.org/10.1056/NEJMoa1112433 PMID: 22670901
13. Migliori GB, Lienhardt C, Weyer K, van der Werf MJ, Blasi F, Raviglione MC. Ensuring rational introduc-
tion and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J.
2014; 44(6):1412–7. https://doi.org/10.1183/09031936.00132114 PMID: 25435528
14. TB Alliance. Available from: https://www.tballiance.org/. [cited 2019 Feb 18].
15. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, et al. Evaluation of a standardized
treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis
(STREAM): study protocol for a randomized controlled trial. Trials. 2014 Sep 9; 15:353. https://doi.org/
10.1186/1745-6215-15-353 PMID: 25199531
16. Trebucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, et al. Treatment outcome
with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis.
2018; 22(1):17–25. https://doi.org/10.5588/ijtld.17.0498 PMID: 29149917
17. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update (WHO/HTM/TB/2016.04).
Geneva: World Health Organisation; 2016.
18. WHO handbook for guideline development. Geneva: World Health Organisation; 2014. Available from:
http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf?ua=1.
19. Food and Drug Administration. Guidance for Industry Exposure–Response Relationships—Study
Design, Data Analysis, and Regulatory Applications. 800–835 (2003). Accessed Feb 18, 2019.
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002769 March 22, 2019 4 / 5
20. World Health Organisation: Target Regimen Profiles for TB Treatment (WHO/HTM/TB/2016.16). (Avail-
able at: http://apps.who.int/iris/bitstream/10665/250044/1/9789241511339-eng.pdf): Geneva: World
Health Organization; 2016. Accessed Feb 18, 2019.
21. Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, et al. Priority-Set-
ting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLoS Med. 2017; 14(1):
e1002202. https://doi.org/10.1371/journal.pmed.1002202 PMID: 28045934
22. Bonnett LJ, Ken-Dror G, Koh GC, Davies GR. Comparing the Efficacy of Drug Regimens for Pulmonary
Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials. Clin Infect Dis 2017; 65(1):46–
54. https://doi.org/10.1093/cid/cix247 PMID: 28402396
23. Lienhardt C, Davies G. Methodological issues in the design of clinical trials for the treatment of multi-
drug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Lung Dis 2010; 14:528–37.
PMID: 20392344
24. Davies GR, Phillips PPJ, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and
solutions. Int J Tuberc Lung Dis 2015; 19(6):626–634. https://doi.org/10.5588/ijtld.14.0988 PMID:
25946350
25. Merle CS, Fielding K, Bah-Sow O, Gninafon M, Lo MB, Mthiyane T, et al. OFLOTUB/Gatifloxacin for
Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J
Med. 2014; 371(17):1588–98. https://doi.org/10.1056/NEJMoa1315817 PMID: 25337748
26. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxiflox-
acin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014; 371(17):1577–87. https://doi.
org/10.1056/NEJMoa1407426 PMID: 25196020
27. Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, et al. High-dose rifa-
pentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014; 371(17):1599–608. https://
doi.org/10.1056/NEJMoa1314210 PMID: 25337749
28. Imperial M, Nahid P, Phillips P, Davies GR, Fielding K, Hanna D, et al. A Patient-Level Pooled Analysis
of Treatment Shortening Regimens for Drug-Susceptible Pulmonary Tuberculosis. Nature Med. 2018;
24(11):1708–15 https://doi.org/10.1038/s41591-018-0224-2 PMID: 30397355
29. World Health Organization. Report of the Technical Consultation on Advances in Clinical Trial Design
for Development of New TB Treatments, Glion-sur-Montreux, Switzerland, 14–16 March 2018. Geneva:
World Health Organization; 2018 (WHO/CDS/TB/2018.17).
30. Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ. Keeping phase III tuberculosis tri-
als relevant: Adapting to a rapidly changing landscape. PLoS Med. 2019;16(3):e1002767. https://doi.
org/10.1371/journal.pmed.1002767
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002769 March 22, 2019 5 / 5
